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Purpose: Monoclonal antibodies (mAbs) are commonly administered by subcutaneous (SC) route. 
However, bioavailability is often reduced after SC administration. In addition, the sequential transfer of 
mAbs through the SC tissue and lymphatic system is not completely understood. Therefore, major 
objectives of this study were a) To understand absorption of mAbs via the lymphatic system after SC 
administration using physiologically based pharmacokinetic (PBPK) modeling, and b) to demonstrate 
application of the model for prediction of SC pharmacokinetics (PK) of mAbs. 
Methods: A minimal PBPK model was constructed using various physiological parameters related to the 
SC injection site and lymphatic system. The remainder of the body organs were represented using a 2-
compartment model (central and peripheral compartments), with parameters derived from available 
intravenous (IV) PK data. The IV and SC clinical PK data of a total of 10 mAbs were obtained from 
literature. The SC PK data were used to estimate the lymphatic trunk-lymph node (LN) clearance. 
Results: The mean estimated lymphatic trunk-LN clearance obtained from 37 SC PK profiles of mAbs was 
0.00213 L/h (0.001332 to 0.002928, 95% confidence intervals). The estimated lymphatic trunk-LN 
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clearance was greater for the mAbs with higher isoelectric point (pI). In addition, the estimated clearance 
increased with decrease in the bioavailability.  
Conclusion: The minimal PBPK model identified SC injection site lymph flow, afferent and efferent lymph 
flows, and volumes associated with the SC injection site, lymphatic capillaries and lymphatic trunk-LN as 
important physiological parameters governing the absorption of mAbs after SC administration. The model 
may be used to predict PK of mAbs using the relationship of lymphatic trunk-LN clearance and the pI. In 
addition, the model can be used as a bottom platform to incorporate SC and lymphatic in vitro clearance 





Physiologically based pharmacokinetic model, monoclonal antibody, subcutaneous, proteolysis, lymph 
flow, lymph node, lymphatic system 
 
INTRODUCTION 
Monoclonal antibodies (mAbs) are an important class of therapeutic proteins (TPs) administered mainly 
via subcutaneous (SC) route due to shorter clinical visits for patients, the possibility of self-administration, 
and its less invasive nature. However, when compared to the intravenous (IV) route, SC injection has 
challenges associated with the incomplete bioavailability and pain-free administration of larger fluid 
volumes (1). The SC tissue and lymphatic system are important barriers for the absorption of mAbs. After 
SC administration, the mAbs travel through the lymphatic vessels and lymph nodes before reaching the 
systemic circulation. The SC bioavailability of mAbs is typically in the range of 52 to 80% (2, 3). 
Proteolysis within the lymphatic system and the SC injection site may be partially responsible for the 
reduced bioavailability of mAbs. The rate of neonatal Fc receptor (FcRn) binding and recycling exceeds 
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the rate of lysosomal/endosomal trafficking of mAbs; therefore, endosomal proteolysis may contribute only 
minimally to low mAb bioavailability (3, 4). In addition, the target mediated drug disposition (TMDD) is 
often saturated due to limited receptors. Thus, mAbs are cleared slowly from the systemic circulation. The 
TPs like IgG1, IgG2 and IgG4 have a long half-life of around 23 days (3), which is substantially longer 
than other proteins of similar molecular weights. Further, the appearance rate of mAbs in the plasma is slow 
(Tmax generally 2-14 days) (3). The low bioavailability of mAbs may result from efficient pre-systemic 
clearance mechanisms or irreversible retention (and subsequent elimination) of significant dose at the 
injection site or in the surrounding tissues.  
 
Charman et al. investigated the causes of reduced bioavailability of human growth hormone (hGH) protein 
using a sheep model. The SC injection site degradation was minimal for hGH, while the lymphatic 
proteolysis was mainly responsible for its reduced bioavailability after SC administration (5). We 
hypothesize that the interstitial proteolysis in the lymphatic system may be responsible for lower 
bioavailability of mAbs after SC administration. In this study, a minimal physiologically based 
pharmacokinetic (PBPK) model was used to understand the sequential transit of mAbs and to estimate 
lymphatic clearance using the SC pharmacokinetics (PK). The model was constructed using physiological 
parameters related to the SC injection site, lymphatic system and the reported clinical IV PK data. This 
study had the following major objectives: a) construction of the minimal PBPK model focusing on the 
lymphatic transit of mAbs after SC administration using physiologically relevant lymph flows and 
compartment volumes, b) estimation of the lymphatic clearance using literature SC PK data, and c) 
identification of the parameters governing the absorption of mAbs via the SC and lymphatic system.  
 
Various PBPK models for TPs have been reported recently and as early as 1995 (Gill et al., Abbuqayyas 
and Balthasar, Garg and Balthasar, Baxter et al., Shah and Betts) (6-9). Some of the authors (Zhao et al., 
Chen et al., Elmeliegy et al., Li et al.) proposed the minimal PBPK approach to eliminate complexity 
associated with the models (3, 10-12). Although, these models may be useful for a mechanistic 
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understanding of the clearance and absorption processes at the SC injection site and in the lymphatic system, 
use of PBPK modeling for TP PK prediction is limited (13). After SC injection, the mAb travels through 
the lymphatic capillary network, lymph nodes, lymphatic trunks and thoracic lymph duct before joining the 
systemic circulation. Hence, in this study, the lymphatic organs were incorporated in the minimal PBPK 
model, and the lymphatic trunk-lymph node (LN) clearance was estimated using the SC PK. Interestingly, 
it appears that the estimated lymphatic trunk-LN clearance was directly proportional to the isoelectric point 
(pI) of the mAb. In addition, the model must be combined in the future with in vitro proteolysis data 
obtained from the lymphatic system to predict SC PK and bioavailability of mAbs. Further, the variability 
in the PK due to different populations, disease conditions, formulations, novel delivery technologies, and 
biophysical properties of the TP may be addressed using the minimal PBPK model (14). Overall, the 
proposed minimal PBPK model can be used for mechanistic understanding mAb absorption and prediction 
of PK after SC administration.  
METHODS 
Digitization of literature IV and SC PK data  
The IV (35 profiles) and SC (37 profiles) PK of 10 mAbs were obtained from literature and digitized using 
WebPlotDigitizer (version 4.1) (15). This web-based tool has been extensively used in other reports (16). 
The IV PK profiles were used to estimate 2-compartment model parameters, while the SC PK profiles were 
used to estimate the lymphatic trunk-LNs clearance.   
Construction of the minimal PBPK model 
The minimal PBPK model was constructed using SimBiology (Matlab R2017a). The physiologically based 
model and simple compartmental model were combined to describe absorption of mAbs after SC 
administration (Figure 1). The model equations describing FcRn binding and transfer across interstitial, 
endosomal and vascular space were adopted from previously reported studies (3, 9, 17). However, 
additional physiological parameters related to the lymphatic system were either calculated or obtained from 
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the literature (Table 1) and used to construct the model. The model parameters specific to mAbs are listed 
in Table 2. Furthermore, additional compartments were included to describe the sequential transfer of mAbs 
through the lymphatic system. It was assumed that the SC dose of mAb distributes equally in the SC 
interstitial space after the injection. 
 
Figure 1: Schematic of the semi-PBPK model for mAb absorption after SC injection 
Physiological parameters related to the SC injection site and lymphatic system 
The physiological parameters related to the SC injection site and lymphatic system were either obtained or 
calculated from the literature (Table 1). The SC injection site volume was calculated by Gill et al. (9) using 
the diameter of the SC injection depot of radiolabeled IgG.  While, the SC site lymph flow was measured 
using the rate of radiolabeled IgG loss from a SC administration site (9). Lymphatic capillary volume was 
calculated using the average distance between the injection site and sentinel LN (30 cm), the lymphatic 
network density per 1 cm annulus of arm skin (385 cm), and the average radius of lymphatic capillaries 
(0.0274 mm) (18-20). Afferent lymph flow was calculated using the reported lymphatic flow rate (40 
mm/min) and radius (0.0274 mm) of the lymphatic capillaries in humans (21, 22). The efferent lymph flow 
rate in sheep was used in the model (23). The volume of the lymphatic trunk was calculated based on an 




Figure 2: Schematic representation of flow of mAbs or TPs after SC injection in thigh 
The total LNs volume was calculated based on the number of LNs (45 to 50) to which the mAb is exposed 
after SC injection in thigh (24-26). The average volume of cervical LNs (0.292 mL) reported in humans 
was used to calculate the total LN volume after SC injection in the upper arm, abdomen, and thigh (27). 
The SC injection of a TP in thigh would lead to its travel through the inguinal, iliac and lumbar LNs (Figure 
2). Upon SC injection in the upper arm, the TP would travel through the cubital and axillary LNs followed 
by the subclavian trunk. After passing through the LNs and lymphatic trunks, TPs would join the central 
lymphatic system (thoracic duct and cysterna chyli), which are lymphatic vessels with greater diameters. 
The TP would join the systemic circulation via the thoracic duct if the SC injection site were left upper arm, 
whereas injections into the right upper arm, would enter either via the right thoracic duct or thoracic lymph 
duct (Figure 3). After abdominal SC injection, the TP would generally travel via inguinal, iliac, and lumbar 
LNs towards the cisterna chyli and thoracic duct, to enter the systemic blood circulation via the subclavian 





Figure 3: Sequential transfer of mAbs towards the systemic circulation after SC injection at, A) Thigh, 
B) Abdomen, and C) Upper Arm 
The lymphatic trunk and LN volumes were combined to calculate the interstitial lymphatic trunk-LN 
volume. The total endosomal volume of LNs was calculated based on the endosomal volume in a peripheral 
mononuclear cell (28) and the number of lymphocytes in a LN (29). The endosomal LN volume and the 
combined lymphatic trunk-LN interstitial volume for various SC injection sites (thigh, abdomen, and upper 
arm) were approximately similar (Table 1).  
The central lymphatic system’s volume was dependent on the site of SC injection. In the case of SC 
injection to the thigh, abdomen or left upper arm, the TP would travel through the thoracic lymph duct. In 
the case of thigh and abdominal injections, volume of the cisterna chyli should be included in the central 
lymphatic volume. For this model, it was assumed that the SC injection site was either thigh or abdomen, 
therefore, the volume of the thoracic duct and cisterna chyli were included in the central lymphatic volume. 
However, the volume of the central lymphatic system after injection in an upper arm or thigh was found to 
be similar, because the volume of the cisterna chyli was negligible as compared to the thoracic duct volume 
(Table 1). Volumes of the thoracic lymph duct and cisterna chyli were calculated based on literature values 
of length and diameter. In the case of the thoracic lymph duct, the length and diameter were 45 and 5 cm, 
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respectively. While, in the case of cisterna chyli, the length and diameter were 2-5 mm and 1 cm, 
respectively (30).  
Table 1: Human physiological parameters related to the SC injection site and lymphatic system 
Parameter Value Reference 
𝑉𝑆𝐶
𝐼  (SC injection site interstitial volume) 0.003115 L (9) 
𝑉𝑆𝐶
𝐸  (SC injection site endosomal volume) 0.000025 L (9) 
𝑉𝑆𝐶
𝑉  (SC injection site vascular volume) 0.00025 L (9) 
𝑉𝐿𝐶𝑎𝑝 (Volume of the lymphatic capillaries) 0.00033 L Calculated (18-20) 
𝑉𝐿𝑌−𝑈𝐴
𝐼  (Combined interstitial volume of lymphatic 
trunk and LNs after SC injection in upper arm)a 
0.01408 L Calculated (24-27) 
𝑉𝐿𝑌
𝐼  (Combined interstitial volume of lymphatic trunk 
and LNs after SC injection in thigh) 
0.01349 L Calculated (25-27, 
31) 
𝑉𝐿𝑌−𝐴𝑏
𝐼  (Combined interstitial volume of lymphatic 
trunk and LNs after SC injection in abdomen)a 
0.01758 L Calculated (25-27, 
32) 
𝑉𝐿𝑌−𝑈𝐴
𝐸  (Combined endosomal volume of all LNs to 
which the mAb is exposed after SC injection in upper 
arm)a 
0.000014 mL Calculated (24-29) 
𝑉𝐿𝑌
𝐸  (Combined endosomal volume of all LNs to 
which the mAb is exposed after SC injection in 
thigh) 
0.0000126 mL Calculated (28, 29, 
31) 
𝑉𝐿𝑌−𝐴𝑏
𝐸  (Combined endosomal volume of all LNs to 
which the mAb is exposed after SC injection in 
abdomen) 
0.00001596 mL Calculated (25-29, 
32) 
𝑉𝐿𝑌−𝐶𝑒𝑛 (Volume of central lymphatic system) 0.00888 L Calculated (30) 
𝑉𝑇ℎ𝑜𝑟 (Volume of thoracic lymph duct)
b 0.00884 L Calculated (30) 
𝑉𝐶𝐶 (Volume of cisterna chyli)
b 0.000039 L Calculated (30) 
𝐿𝑆𝐶 (Lymph flow at the SC injection site) 0.0001356 L/h  (9) 
𝐿𝐴𝑓𝑓 (Lymph flow afferent to LNs in human) 0.00000564 L/h Calculated (21, 22) 
𝐿𝐸𝑓𝑓 (Lymph flow efferent to LNs in sheep) 0.00387 L/h (23) 
𝐿𝑇ℎ𝑜𝑟 (Thoracic duct lymph flow rate) 0.06 L/h (33, 34) 
𝑄𝑆𝐶 (Blood flow at the SC injection site) 0.04992 L/h  (9) 
𝐶𝐸𝑛𝑑𝑜 (Concentration of endogenous mAb in 
endosomal compartment) 
10000 mg/L (3) 
𝐾𝑑 (Dissociation constant for antibody FcRn 
binding) 
45.36 mg/L (35) 
𝑛𝑃𝑡 (FcRn concentration in SC tissue or LNs) 2880 mg/L (36) 
aNot used in the model (SC injection site was assumed as thigh) 
bUsed to calculate total central lymphatic volume 
 
Table 2: mAb related parameters used in the minimal PBPK model 
Parameter Value Reference 
𝑉  (Vascular reflection coefficient) 0.95 (3, 17) 
𝐿 (Lymphatic reflection coefficient) 0.2 (3, 17) 
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𝑅1 (Endosomal uptake rate of antibody) 0.00000926 /h (3, 4) 
𝑅2 (Endosomal return rate of antibody) 0.26 /h (3, 4) 
𝐹𝑅 (Recycling fraction of FcRn bound mAb) 0.715 (3) 
𝐶𝐿𝐸𝑛𝑑𝑜−𝑆𝐶 (Endosomal clearance of mAb in SC injection 
site)a 
0.003675 L/h (17) 
𝐶𝐿𝐸𝑛𝑑𝑜−𝐿𝑌 (Endosomal clearance of antibody in LNs)
b 0.0001254 L/h (17) 
aEndosomal clearance in skin assumed to be similar to SC injection site 
bEndosomal clearance in spleen assumed to be similar to lymphatic trunk-LN 
Parameter estimation and sensitivity analysis 
A nonlinear mixed-effects model with stochastic EM algorithm was used for estimation of the 2-
compatmental IV PK parameters. The lymphatic trunk-LN clearance was estimated using either the 
nonlinear mixed-effects model with stochastic EM algorithm or a nonlinear least squares solver. Sensitivity 
analysis was performed on the physiological, mAb related and estimated parameters (Supplementary Figure 
1 and 2). The parameters were altered by 0.1-, 0.3-, 0.5-, 0.7-, 1-, 3-, 5-, 7-, 10-, 50- and 100-fold of the 
original values as mentioned in Table 1. The lymphatic reflection coefficient was altered by 0.1-, 0.3-, 0.5-
, 0.7-, 1-, 1.5-, 2-, 2.5-, 3-, 3.5-, 4-, 4.5-, 5- folds of the original parameter value and its impact on the PK 




The model was validated by comparing observed and predicted PK profiles after SC administration. In 
addition, accuracy of the predictions was assessed by plotting ratios of Tmax-observed/Tmax-predicted, Cmax-
observed/Cmax-predicted with the pI, lymphatic trunk-LN clearance, and bioavailability (Supplementary Figure 3, 
4 and 5). The bioavailability and pI values for mAbs were obtained from the literature (37-50). In the case 
of anifrolumab, the pI value was estimated using the amino acid sequence (51) and ProtParam, a web-based 




Estimation of the 2-compartment IV parameters 
The 2-compartment model was used to estimate the parameters using the literature PK data after IV bolus 
or infusion (Table 3). These parameters were different for each mAb, and they were fixed in the minimal 
PBPK model. The mAbs had average volume of 3.5571 L (standard deviation,  1.1081) for the central 
compartment and 1.8069 L (standard deviation,  1.0308) for the peripheral compartment. Mean values for 
CLcen, K12 and K21 were 0.01531 L/h, 0.0992 /h and 0.3448 /h, respectively. 
Table 3: The 2-compartmental model parameters for various mAbs after IV administration 
mAb Vcen (L) Vper (L) CLcen (L/h) K12 (/h) K21 (/h) Reference 
Adalimumab 3.2131 2.2382 0.01023 0.01162 0.01669 (53) 
Anifrolumab 2.1732 3.7869 0.0111 0.02024 0.01161 (54) 
Belimumab 3.0486 2.3877 0.009602 0.01635 0.0208 (43, 44) 
Canakinumab 3.2897 2.3638 0.007541 0.009417 0.0131 (40) 
Daclizumab 5.5255 1.762 0.01104 0.00257 0.00805 (55) 
Golimumab 2.3293 2.3279 0.01467 0.01302 0.01302 (42, 56) 
Guselkumab 4.9381 0.4131 0.0233 0.000871 0.0104 (46) 
Infliximab 4.5782 1.2645 0.0169 0.8914 3.2276 (57) 
Tocilizumab 3.5145 1.0064 0.03585 0.01084 0.0378 (58) 
Trastuzumab 2.9608 0.5186 0.01291 0.0157 0.0896 (59, 60) 
Mean 3.5571 1.8069 0.01531 0.0992 0.3448  
Standard 
deviation 
1.1081 1.0308 0.00849 0.2784 1.0131  
 
 
Estimation of the lymphatic trunk-LN clearance 
A single parameter (lymphatic trunk-LN clearance) was estimated and the rest of the model was fixed using 
literature values as described in the methods section. The clearance represents proteolysis of mAbs in the 
interstitial space of the lymphatic trunks and LNs (Figure 4). The model predicted a total of 37 SC PK 
profiles (10 mAbs with 26 different doses), which were compared with the mean observed published data 
(Figure 5 and 6). However, in the case of belimumab, the patient-PK profile was a geometric mean. The 
estimated lymphatic trunk-LN clearance was in the range of 0.0001495 to 0.007776 L/h with a mean of 
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0.00213 L/h (0.001332 to 0.002928, lower and upper 95% confidence intervals of the mean) for a total of 
37 SC PK profiles. Average lymphatic trunk-LN clearance values for each mAb are shown in Table 4. 
 
Figure 4: Estimated lymphatic trunk-LN clearance for a) all mAbs used in this study, b) individual 




Table 4: Estimation of lymphatic trunk-LN clearance after SC administration of mAbs 
mAb (SC 
injection site) 
SC Dose and (F) Population Ref. 





40 mg (64%) Healthy volunteers (39) 0.00192 L/h 
Anifrolumab 
(Abdomen) 















200, 2*120, 240 mg 
(76%) 
Healthy volunteers (44) 0.00000024 L/h 
Canakinumab 
(NA) 
150, 300 mg (70 %) Healthy volunteers (40) 0.001116 L/h 
Daclizumab** 
(NA) 



















100 mg (on day 0, 28 








162 mg (49%) Healthy volunteers (58) 0.002085 L/ha 
Tocilizumab 
(Thigh) 
162 mg (with 
hyaluronidase) 
Healthy volunteers (63) 0.0006258 L/ha,b 
Trastuzumab 
(Thigh) 
482, 645, and 776 mg 
(with hyaluronidase)  
Healthy volunteers (64) 0.001621 L/ ha,c 
Trastuzumab 
(Thigh) 





(64) 0.0004889 L/ha,d 
Trastuzumab 
(Thigh) 
600 mg (with 
hyaluronidase) 
Healthy volunteers (65) 0.001839 L/ha,e 
Mean CLLN: 0.00213 L/h (Standard deviation: 0.002359, lower 95% confidence interval of the mean: 
0.001332, upper 95% confidence interval of the mean: 0.002928 L/h) 
Nonlinear mixed-effects model with stochastic EM algorithm used for estimation of the parameters 
unless indicated. All observed SC PK data were mean values unless indicated. 
aNonlinear least squares solver 
bSC Site lymph flow (0.04474 L/h) and CLLN estimated simultaneously 
cSC Site lymph flow (0.002798 L/h) and CLLN estimated simultaneously 
dSC Site lymph flow (0.003112 L/h) and CLLN estimated simultaneously 
eSC Site lymph flow (0.01307 L/h) and CLLN estimated simultaneously 
F: Bioavailability after SC administration 
*Geometric mean of the observed pharmacokinetic data  
**The model simulated median pharmacokinetic data 
CLLN: Clearance of mAb in the lymphatic trunk-LN interstitial compartment 




Applications of the minimal PBPK model to evaluate impact of hyaluronidase in the mAb 
formulation 
The mAbs for the SC administration are formulated as highly concentrated solutions in order to deliver 
higher doses (typically 500-900 mg). The injection volume cannot be increased more than 1-2 mL due to 
injection discomfort (66). However, hyaluronidase has been used in several studies to allow higher injection 
volumes by disrupting the complex network of the SC extracellular matrix formed by hyaluronic acid. In 
addition, the hyaluronidase enzyme can increase the rate of TP absorption leading to decreased Tmax, 
increased Cmax, increased area under the curve (AUC), and enhanced bioavailability of the TPs (66, 67). In 
this study, the SC PK data obtained after co-formulation of hyaluronidase, and tocilizumab and trastuzumab 
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were used to estimate the lymphatic trunk-LN clearance (58, 63-65). Due to the co-formulation with 
hyaluronidase, Tmax was over-predicted for tocilizumab and trastuzumab. The Observed Tmax/Predicted Tmax 
ratio for tocilizumab and trastuzumab was 0.58 and 0.6, respectively. We hypothesized that the alteration 
of SC injection site by hyaluronidase may lead to altered SC injection site lymph flow. Therefore, lymphatic 
trunk-LN clearance and SC injection site lymph flow were estimated simultaneously (Table 4). After the 
simultaneous estimation of both the parameters, Tmax prediction was improved for tocilizumab (Observed 
Tmax/Predicted Tmax= 0.87). Similarly, trastuzumab Tmax prediction accuracy was also improved (Observed 
Tmax/Predicted Tmax= 0.82). The estimated SC injection site lymph flow for the co-formulation of the mAb 
and hyaluronidase was higher when compared to the original lymph flow used in the model. The estimated 
SC injection site lymph flow for tocilizumab was 0.04474 L/h, which was 330-fold higher than the minimal 
PBPK model’s value (Table 1). In the case of trastuzumab, the average SC injection site lymph flow was 
0.002955 L/h (22-fold higher than the original value) for healthy volunteers and HER2-positive breast 
cancer patients (64) (observed and model estimated PK profiles shown in Figure 6). In the case of other SC 
PK profile (65) (data not shown) obtained from the healthy volunteers, SC site lymph flow was 0.01307 
L/h (96-fold higher than the original value).  
 
In addition to above analysis, the SC PK (tocilizumab) profiles obtained without co-formulation with 
hyaluronidase enzyme were also used for simultaneous estimation of the SC injection site lymph flow and 
lymphatic trunk-LN clearance using the minimal PBPK model. This was done to demonstrate that the 
change in the SC site lymph flow observed previously was in fact due to co-formulation of hyaluronidase 
and mAbs. In the case of tocilizumab without hyaluronidase, the SC site lymph flow was 0.0009557 L/h 
(only 7-fold higher than the original value). This proves that the SC injection site lymph flow was altered 
when hyaluronidase co-formulation strategy was used. For the SC profiles where this strategy was not used, 




Figure 5: Observed and the model fitted SC PK profiles. a) adalimumab, b) anifrolumab, c) 
belimumab-Healthy, d) belimumab-patients, e) canakinumab, and f) daclizumab (Mean observed PK 
profiles were used for comparison with the model estimates. Observed belimumab-patient PK profile 








Figure 6: Observed and the model fitted SC PK profiles. g) golimumab, h) guselkumab, i) infliximab, j) 
tocilizumab, and k) trastuzumab (Mean observed PK profiles were used for comparison with the model 
estimates) 
Comparison of lymphatic trunk-LN clearance with pI and bioavailability of mAbs 
The estimated lymphatic trunk-LN clearance was compared with the pI (Figure 7) and bioavailability 
(Figure 8) of mAbs. The interstitial space has overall anionic charge due to cell surface of various immune 
cells in the LNs. The mAbs with higher pI had higher values of the estimated lymphatic trunk-LN clearance. 
The lymphatic trunk-LN clearance increased with decrease in bioavailability (obtained from literature) of 
the mAbs (Figure 8). This suggests that the model accounted for the lymphatic proteolysis of mAbs after 









Figure 7: Correlation of the model estimated lymphatic trunk-LN clearance with the isoelectric point a) 
Linear scale, b) Logarithmic scale 
 
 
Figure 8: Correlation of the model estimated lymphatic trunk-LN clearance with the bioavailability a) 
Linear scale, b) Logarithmic scale (Trastuzumab: Co-formulated with hyaluronidase. Tocilizumab: 
Only one sample co-formulated with hyaluronidase.) 
Sensitivity analysis  
The sensitivity analysis showed that the SC injection site interstitial volume (𝑉𝑆𝐶
𝐼 ), SC lymph flow (𝐿𝑆𝐶), 
and lymphatic capillary volume (𝑉𝐿𝐶𝑎𝑝), and afferent lymph flow (𝐿𝐴𝑓𝑓) were responsible for changes in 
Cmax and Tmax of mAbs (Supplementary Figure 1). In the case of lymphatic trunk-LN interstitial volume 
(𝑉𝐿𝑌
𝐼 ), increases of the volume by 50- and 100-fold lead to alterations of mAb PK profiles, while changes 
by 0.1 to 10-fold of the original value did not alter Cmax or Tmax. The alteration of lymphatic trunk-LN 
clearance (𝐶𝐿𝐿𝑁) and efferent lymph flow (𝐿𝐸𝑓𝑓) mainly lead to modification of the Cmax. In addition, 
changes in the thoracic duct lymph flow (𝐿𝑇ℎ𝑜𝑟) and central lymphatic volume (𝑉𝐿𝑌−𝐶𝑒𝑛) did not impact 
PK of mAbs. This indicates that transit through the initial lymphatic system after SC injection is the rate 
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determining step for mAb absorption instead of the thoracic duct. Therefore, SC injection site volume, SC 
injection site lymph flow, lymphatic capillary volume, afferent lymph flow, and efferent lymph flow are 
important physiological parameters for absorption of mAbs. Change in the thoracic duct lymph flow and 
central lymphatic volume did not alter the PK of mAbs (Supplementary Figures 1). Both the Cmax and Tmax 
were sensitive to change in the SC injection site volume, SC injection site lymph flow, lymphatic capillary 
volume, and afferent lymph flow (Supplementary Figures 3 to 7). However, changes in the efferent lymph 
flow had no impact on Tmax. In addition, when the lymphatic reflection coefficient was increased; Cmax 
decreased, while Tmax increased. There was no change in the PK profile after alteration of the vascular 
reflection coefficient (Supplementary Figure 2). 
Model validation 
Accuracy of the model prediction was evaluated by plotting observed and predicted values of Cmax and Tmax 
(Supplementary Figure 8). In addition, the ratio of observed and predicted Cmax and Tmax were plotted with 
the pI, lymphatic trunk-LN clearance, and bioavailability (Supplementary Figure 9, 10, and 11). In the case 
of Cmax, all predicted values were within 1.2-to 0.5-fold of the observed literature values. The predicted Tmax 
was within the range of 1.8 to 0.3-fold of the observed values.  
DISCUSSION 
In this manuscript, the sequential transfer of mAbs after SC administration via the lymphatic system is 
described using the minimal PBPK model. The SC injection site (interstitial, endosomal, vascular), 
lymphatic capillaries, lymphatic trunk-LNs (interstitial and endosomal), central lymphatic system (thoracic 
duct and cisterna chyli) compartments were used to describe the transit of mAbs after SC administration. 
The rest of the body was modeled with a 2-compartment model based on the literature IV PK data. The 
sequential transfer was based on the known anatomy of lymphatic system (24-27). However, detailed routes 
of TP transfer via different LNs remain to be investigated further. Also, some individuals may have 
alterations in the clearance patterns, for example the clearance in the arm, shoulder and thigh may be 
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significantly changed after radical mastoidectomy. In addition, an injection site may clear into multiple 
adjacent lymph basins. 
The clearance from the interstitial space of the SC injection site was not considered in the model, because 
a previously reported study indicated that protein (hGH) degradation was minimal at the SC injection site 
(5). In addition, simultaneous estimation of the clearance from the SC interstitial space and lymphatic trunk-
LN interstitial compartment resulted in a minor contribution for the SC injection site proteolysis (data not 
shown). However, the endosomal proteolysis in the SC injection site and LNs was considered. The 
lymphatic trunk-LN interstitial clearance was estimated using the minimal PBPK model and the literature 
SC PK data (Figure 4 and Table 4). The estimated clearance differed with dosing and population changes. 
This alteration of the estimated clearance may be due to disease condition, change in formulation, or the 
differences in posttranslational modifications (e.g. glycosylation). These differences were not considered 
in the model. The model demonstrated that the estimated lymphatic trunk-LN clearance of mAbs may 
correlate with the bioavailability (Figure 8). The estimated clearance increased when the bioavailability of 
the mAb decreased. This indicates efficiency of the model to account for the proteolysis of mAbs in the 
lymphatic system. According to the previously published reports, proteolysis was not observed after 
incubation of TPs with the freshly collected lymph, indicating absence of any protease enzymes in the 
lymph (5, 68). In this study, the lymphatic trunk volume (which mainly contains lymph fluid) and the LN 
(which mainly contains lymph node cells) volume were combined to represent the compartment responsible 
for proteolysis of the mAbs. The lymphatic trunk-LN compartment was mainly composed of the LN 
volume. The lymphatic trunk volume representing volume of the lymph fluid was very minor ( 7%). 
Sensitivity analysis (Supplementary Figure 1) showed that the lymphatic trunk-LN interstitial space 
proteolysis was important to govern Cmax of the mAbs. The degradation of mAbs in the lymphatic system 
was primarily due to extracellular or interstitial proteolysis. The protease enzymes secreted by the LN and 
other immune cells in the interstitial space may play an important role in reducing the bioavailability of 
mAbs. Intracellular or endosomal proteolysis of mAbs was negligible due to FcRn binding-mediated 
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protection. The intracellular proteolysis of mAbs in the lymphatic system may be dependent on their uptake 
by the lymphocytes. In this model, we used endosomal uptake rate (R1) from a literature PBPK model 
(estimated by fitting liver data) (3, 4). Alteration of the endosomal uptake rate by 0.1 to 100-fold of the 
original value did not change the PK of mAbs (data not shown). However, in vitro studies to calculate R1 
may be useful for an accurate understanding of proteolytic processes in the SC injection site and lymphatic 
system. Disease conditions like inflammation may also increase proteolytic activity of the lymph. However, 
this remains to be further investigated. Further, alteration of the recycling fraction of FcRn bound mAb, 
dissociation constant for antibody FcRn binding, and FcRn concentration did not change PK of mAbs (data 
not shown). 
Wang et al. (68) confirmed proteolysis of erythropoietin in the presence of rat LN cell suspension. When 
number of LN cells in the incubation was increased, the protein completely disappeared. This indicates that 
LNs are responsible for proteolysis of TPs. In addition, after incubation of the protein with the SC tissue 
homogenate, 90-95% of the parent protein remained unaffected (68). Although the authors raised doubts 
about loss of proteolytic activity during preparation of the SC tissue homogenate, this finding corroborates 
our conclusion that the SC site degradation plays a minor role in governing the bioavailability. However, 
in another study, insulin was reported to degrade at the SC injection site (69). Detailed investigation of in 
vitro proteolysis of mAbs in various systems must be done to arrive at more definite conclusions about the 
cause of reduced bioavailability after SC administration.   
The PK studies in humans indicate that variation in the injection site (abdomen and thigh) do not have any 
impact on Cmax and AUC0-∞ of belimumab (44). In another clinical study, golimumab’s median Tmax after 
SC injection in the thigh was 1.25-fold higher than SC injection in the abdomen and upper arm. The Cmax 
after thigh SC injection was 1.33-fold higher than SC injection in the upper arm, and the Cmax-abdomen was 
1.24-fold higher than that of the upper arm (42). This suggests that the volumes of lymphatic compartments 
and lymph flows may not be significantly different for each of the SC injection sites. Therefore, lymphatic 
volumes and flows rates for one injection site may be applied to the other. The calculations used in the 
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model showed that the interstitial volume of the lymphatic trunk-LN was similar for various SC injection 
sites (upper arm, abdomen, and thigh) (Table 1).  
The prediction accuracy of the model was determined by plotting observed and predicted PK parameters 
(Supplementary Figure 8). There was no correlation of the prediction accuracy of Tmax or Cmax with the pI 
or bioavailability or the estimated lymphatic trunk-LN clearance of mAbs. This confirms that the pI of 
mAbs did not affect the uptake by lymphatic system. Similarly, lymphatic trunk-LN clearance and 
bioavailability did not govern the prediction accuracy of the model.  
 
The model also showed that for the mAbs with higher pI, the estimated lymphatic trunk-LN clearance was 
greater. The cationic proteins with higher pI have a propensity to bind with the anionic cell surfaces and 
interstitial space (e.g. hyaluronic acid). Higher pI also leads to faster clearance of mAbs (70). Similar trend 
was observed for the mAbs investigated in this study (Figure 7). This correlation may be used to predict 
the lymphatic trunk-LN clearance based on the known pI of mAbs. The lymphatic clearance can be used in 
the minimal PBPK model to predict SC PK of the mAbs. 
 
Sensitivity analysis of the model parameters indicated that the initial lymphatics are rate determining for 
absorption of mAbs via the SC route. Mainly, the SC injection site lymph flow, SC injection site volume, 
afferent lymph flow, efferent lymph flow, and lymphatic trunk-LN volume impacted Tmax, after their 
alteration by 0.1 to 100-fold of the original value. However, thoracic duct lymph flow had no effect on Tmax 
even after 0.1 to 100-fold changes in its value. The thoracic lymph duct, which is the largest lymphatic 
vessel, may not change the rate of transit of mAbs. Therefore, alteration of thoracic lymph duct flows due 
to disease condition may not alter overall PK of mAbs. However, the parameters associated with the initial 
lymphatic system are important to govern the absorption of mAbs and change in those parameters due to 




It was reported earlier that the PK of mAbs is prone to high inter-subject variability. Factors like body 
weight, age, sex, ethnicity, disease condition, immune status are responsible for variations in the PK (71). 
However, more research is needed to evaluate their influence on physiological parameters related to the SC 
injection site and lymphatic system. The minimal PBPK model may be used for prediction of bioavailability 
of mAbs using in vitro lymphatic proteolysis data and to evaluate the impact of changes in lymphatic flow 
rates on the PK. In addition, the model may be utilized to guide in vitro experiments for mechanistic 
prediction of the bioavailability. This study has explained various physiological parameters related to the 
SC injection site and lymphatic system responsible for regulating the PK of mAbs.  
 
CONCLUSION 
The lymphatic trunk-LN clearance was estimated using the minimal PBPK model. The physiological 
parameters related to the SC tissue and lymphatic system were used along with the 2-compartment IV 
parameters to construct the minimal PBPK model for prediction of SC PK of the mAbs. The model may 
serve as a platform to utilize the in vitro clearance data from the SC tissue and lymphatic system to predict 
SC PK of mAbs. The LNs were mainly responsible for proteolysis of mAbs leading to their reduced 
bioavailability. Therefore, LN cell suspension may be used to generate inputs for the PBPK model. 
However, the in vitro studies were beyond the scope of this manuscript.  Further, this study identified SC 
injection site lymph flow, afferent lymph flow, efferent lymph flow, volumes associated with the SC 
injection site, and lymphatic trunk-LN clearance as important parameters responsible for absorption of 
mAbs. The lymphatic trunk-LN clearance increased with increase in the pI of mAbs. Therefore, the pI of 
mAbs can be used to calculate the lymphatic clearance. Overall, the model is useful to understand 
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) = ((1 − 𝑉) × 𝐿𝑆𝐶 × 𝐶𝑆𝐶
𝑉 ) − (𝑅1 × 𝐶𝑆𝐶
𝐼 ) + ((1 − 𝐹𝑅) × 𝑅2 × (1 − 𝑓𝑢𝑆𝐶) × 𝐶𝑆𝐶
𝐸 )









) = − ((1 − 𝑉) × 𝐿𝑆𝐶 × 𝐶𝑆𝐶
𝑉 ) − ((𝑄𝑆𝐶 − 𝐿𝑆𝐶) × 𝐶𝑆𝐶
𝑉 ) + (𝐹𝑅 × 𝑅2 × (1 − 𝑓𝑢𝑆𝐶) × 𝐶𝑆𝐶
𝐸 )
− (𝑅1 × 𝐶𝑆𝐶
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𝐼 ) − (𝐹𝑅 × 𝑅2 × (1 − 𝑓𝑢𝑆𝐶) × 𝐶𝑆𝐶
𝐸 ) − ((1 − 𝐹𝑅) × 𝑅2 × (1 − 𝑓𝑢𝑆𝐶) × 𝐶𝑆𝐶
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+ (𝑅1 × 𝐶𝑆𝐶
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) = (𝐿𝑇ℎ𝑜𝑟 × 𝐶𝐿𝑁−𝐶𝑒𝑛) + ((𝑄𝑆𝐶 − 𝐿𝑆𝐶) × 𝐶𝑆𝐶
𝑉 ) − (𝐶𝐿𝐶𝑒𝑛 × 𝐶𝐶𝑒𝑛) − (𝐾12 × 𝐶𝐶𝑒𝑛)
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1
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𝐸 )2 − (4 × (𝐶𝐸𝑛𝑑𝑜 + 𝐶𝑆𝐶
𝐸 ) × 𝑛𝑃𝑡))) 
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𝑉  Concentration of mAb in the vascular space of SC injection site 
𝐶𝑆𝐶
𝐼  Concentration of mAb in the interstitial space of SC injection site 
𝐶𝑆𝐶
𝐸  Concentration of mAb in the endosomal space of SC injection site 
𝐶𝐿𝐶𝑎𝑝 Concentration of mAb in the lymphatic capillary compartment 
𝐶𝐿𝑁
𝐼  Concentration of mAb in the interstitial space of lymphatic trunk-LNs 
𝐶𝐿𝑁
𝐸  Concentration of mAb in the endosomal space of lymphatic trunk-LNs 
𝐶𝐿𝑌−𝐶𝑒𝑛 Concentration of mAb in the central lymphatic system 
𝐶𝐶𝑒𝑛 Concentration of mAb in the central compartment 
𝐶𝑃𝑒𝑟 Concentration of mAb in the peripheral compartment 
𝑉𝑆𝐶




𝑉  SC injection site vascular volume 
𝑉𝑆𝐶
𝐸  SC injection site endosomal volume 
𝑉𝐿𝐶𝑎𝑝 Volume of the lymphatic capillaries 
𝑉𝐿𝑁
𝐼  Combined interstitial volume of lymphatic trunk-LNs after SC injection in thigh 
𝑉𝐿𝑁
𝐸  
Combined endosomal volume of all LNs to which the mAb is exposed after SC 
injection in thigh 
𝑉𝐿𝑌−𝐶𝑒𝑛 Volume of central lymphatic system 
𝑉𝐶𝑒𝑛 Volume of the central compartment 
𝑉𝑃𝑒𝑟 Volume of the peripheral compartment 
𝐿𝑆𝐶 Lymph flow at the SC injection site 
𝐿𝐴𝑓𝑓 Lymph flow afferent to LNs 
𝐿𝐸𝑓𝑓 Lymph flow efferent to LNs 
𝐿𝑇ℎ𝑜𝑟 Thoracic duct lymph flow 
𝑄𝑆𝐶 Blood flow at the SC injection site 
𝐿 Lymphatic reflection coefficient 
𝑉  Vascular reflection coefficient 
𝐶𝐿𝐿𝑁 Clearance of mAb in the lymphatic trunk-LN interstitial compartment 
𝐶𝐿𝐸𝑛𝑑𝑜−𝑆𝐶 Endosomal clearance of mAb in the SC injection site 
𝐶𝐿𝐸𝑛𝑑𝑜−𝐿𝑁 Endosomal clearance of mAb in LNs 
𝐶𝐿𝐶𝑒𝑛 Clearance of mAb from the central compartment 
𝐾12 Transfer rate constant from the central compartment to the peripheral compartment 
𝐾21 Transfer rate constant from the peripheral compartment to the central compartment 
𝑓𝑢𝑆𝐶 Unbound fraction of mAb in SC tissue 
𝑓𝑢𝐿𝑁 Unbound fraction of mAb in lymphatic trunk and LNs 
𝐶𝐸𝑛𝑑𝑜 Concentration of endogenous mAb in endosomal compartment 
𝑅1 Endosomal uptake rate of antibody 
𝑅2 Endosomal return rate of antibody 
𝐹𝑅 Recycling fraction of FcRn bound mAb 
𝐾𝑑 Dissociation constant for antibody FcRn binding 
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